SVF
Insufficient· Insufficient EvidenceNarrative Review

The Functions and Mechanisms of TGF-β3 Signalling in Controlling the Fate Determinations of Various Types of Stem Cells.

Kuang L., Xiang J., He Z.

Narrative Review on Face & Skin, Hair & Scalp, published in J Cell Physiol (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Cell Physiol (2026)
Country
United States
Reported sample size
—
PMID
41700496
DOI
10.1002/jcp.70152

Abstract (original English)

The fate determinations of stem cells are governed by signalling molecules and pathways, and notably, the TGF-β superfamily members play pivotal roles in mediating these decisions. Significantly, TGF-β3 participates in affecting the development of stem cells and their microenvironment. In this review, we address the functions and regulatory networks of TGF-β3 in the fate decisions of several types of stem cells, including neural stem cells, haematopoietic stem cells, odontogenic stem cells, hair-follicle stem cells, adipose-derived stem cells, and mesenchymal stem cells. Specifically, we discuss the biosynthesis, activation, the roles, and mechanisms of TGF-β in influencing the proliferation, differentiation, and cell death of these stem cells, and we further highlight the perspective in this field. TGF-β signalling in stem cells begins with the activation of either integrin-dependent or integrin-independent pathways by binding to cell surface receptors TbRII and TbRI and co-receptor Betaglycan (TR3). TGF-β acts via both classical Smad signalling pathways and a variety of non-classical pathways. Notably, the biological functions of TGF-β3 depend primarily on specific cell type and the existing conditions of stem cells, reflecting the integration of multiple factors including the concentration, duration of action, interactions with other genes and/or non-coding RNAs. This review

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansSignal TransductionTransforming Growth Factor beta3AnimalsCell DifferentiationStem CellsCell ProliferationCell Lineage
Face & SkinHair & Scalp
View on PubMedDOI

Related research